So it is not reasonable to make clinical decisions based on PSA alone, a strategy that will frequently detect clinically insignificant PCa and miss clinically significant prostate cancers (csPCa, Gleason score ≥7) (7). The gene discussed is KLK3; the disease is prostate carcinoma.